<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">19791828</PMID>
      <DateCompleted>
        <Year>2010</Year>
        <Month>01</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1179-1950</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>69</Volume>
            <Issue>15</Issue>
            <PubDate>
              <Year>2009</Year>
              <Month>Oct</Month>
              <Day>22</Day>
            </PubDate>
          </JournalIssue>
          <Title>Drugs</Title>
          <ISOAbbreviation>Drugs</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Saxagliptin.</ArticleTitle>
        <Pagination>
          <StartPage>2103</StartPage>
          <EndPage>2114</EndPage>
          <MedlinePgn>2103-14</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2165/11201170-000000000-00000</ELocationID>
        <Abstract>
          <AbstractText>Saxagliptin and its active metabolite M2 are dipeptidyl peptidase-4 inhibitors that improve glycaemic control by preventing the inactivation of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide. This increases GLP-1 levels, stimulates insulin secretion and reduces postprandial glucagon and glucose levels. In well designed, 24-week trials in treatment-naive patients with type 2 diabetes mellitus, monotherapy with oral saxagliptin 2.5 or 5 mg once daily significantly improved glycaemic control, as measured by mean glycosylated haemoglobin (HbA(1c)) levels, relative to placebo. In large, well designed, 24-week trials, combination therapy with saxagliptin 5 mg once daily plus metformin significantly improved HbA(1c) levels relative to single-agent saxagliptin or metformin in treatment-naive patients; in treatment-experienced patients with inadequate glycaemic control, the addition of saxagliptin 2.5 or 5 mg once daily to metformin, glyburide or a thiazolidinedione, significantly improved HbA(1c) levels relative to continued use of existing monotherapy. Saxagliptin as monotherapy or in combination with other oral antihyperglycaemics was generally well tolerated, with most adverse events being of mild to moderate severity. In clinical trials, the incidence of hypoglycaemic events in patients receiving saxagliptin was generally similar to that in patients receiving placebo or other oral antihyperglycaemic agents. Saxagliptin therapy was not associated with an increased risk of cardiovascular events according to pooled data from eight clinical trials. Saxagliptin generally had a weight-neutral effect.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dhillon</LastName>
            <ForeName>Sohita</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Adis, Auckland, New Zealand. demail@adis.co.nz</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weber</LastName>
            <ForeName>Juliane</ForeName>
            <Initials>J</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>New Zealand</Country>
        <MedlineTA>Drugs</MedlineTA>
        <NlmUniqueID>7600076</NlmUniqueID>
        <ISSNLinking>0012-6667</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054873">Dipeptidyl-Peptidase IV Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>89750-14-1</RegistryNumber>
          <NameOfSubstance UI="D052216">Glucagon-Like Peptide 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9100L32L2N</RegistryNumber>
          <NameOfSubstance UI="D008687">Metformin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SX6K58TVWC</RegistryNumber>
          <NameOfSubstance UI="D005905">Glyburide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054873" MajorTopicYN="N">Dipeptidyl-Peptidase IV Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D052216" MajorTopicYN="N">Glucagon-Like Peptide 1</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005905" MajorTopicYN="N">Glyburide</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2009</Year>
          <Month>10</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2009</Year>
          <Month>10</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2010</Year>
          <Month>1</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">19791828</ArticleId>
        <ArticleId IdType="doi">10.2165/11201170-000000000-00000</ArticleId>
        <ArticleId IdType="pii">5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Diabetes Obes Metab. 2008 May;10(5):376-86</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18355324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Care. 2009 Jan;32(1):193-203</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18945920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Care. 2007 Jun;30(6):1344-50</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17337494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>JAMA. 1999 Jun 2;281(21):2005-12</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10359389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curr Med Res Opin. 2009 Oct;25(10):2401-11</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19650754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curr Opin Endocrinol Diabetes Obes. 2007 Apr;14(2):98-107</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17940427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Care. 2009 Jan;32 Suppl 1:S62-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19118289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ann Pharmacother. 2007 Jan;41(1):51-60</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17190843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Int J Clin Pract. 2009 Sep;63(9):1395-406</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19614786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Circulation. 2008 Jan 29;117(4):574-84</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18227398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Obes Metab. 2009 Jun;11(6):611-22</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19515181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drug Metab Dispos. 2009 Jun;37(6):1164-71</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19251818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Care. 2009 Sep;32(9):1649-55</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19478198</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
